# Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

> **NCT03271554** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 355 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Alectinib

## Key facts

- **NCT ID:** NCT03271554
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-09
- **Primary completion:** 2021-05-28
- **Final completion:** 2021-05-28
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2022-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03271554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03271554, "Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03271554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*